|
1
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma
of the Bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S, et al: Epidemiology and risk factors of urothelial
bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stenzl A, Cowan NC, De Santis M, Kuczyk
MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: European
Association of Urology (EAU): Treatment of muscle-invasive and
metastatic bladder cancer: Update of the EAU guidelines. Eur Urol.
59:1009–1018. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye F, Wang L, Castillo-Martin M, McBride
R, Galsky MD, Zhu J, Boffetta P, Zhang DY and Cordon-Cardo C:
Biomarkers for bladder cancer management: Present and future. Am J
Clin Exp Urol. 2:1–14. 2014.PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang SJ, Weng SL, Hsieh JY, Wang TY,
Chang MD and Wang HW: MicroRNA-34a modulates genes involved in
cellular motility and oxidative phosphorylation in neural
precursors derived from human umbilical cord mesenchymal stem
cells. BMC Med Genomics. 4:652011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu
X, Zhan B, Piao C and Jiang Z: miR-130b, an onco-miRNA in bladder
cancer, is directly regulated by NF-κB and sustains NF-κB
activation by decreasing Cylindromatosis expression. Oncotarget.
7:48547–48561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song T, Zhang X, Yang G, Song Y and Cai W:
Decrement of miR-199a-5p contributes to the tumorigenesis of
bladder urothelial carcinoma by regulating MLK3/NF-κB pathway. Am J
Transl Res. 7:2786–2794. 2015.PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee JY, Ryu DS, Kim WJ and Kim SJ:
Aberrantly expressed microRNAs in the context of bladder
tumorigenesis. Investig Clin Urol. 57 Suppl 1:S52–S59. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B,
Man X and Kong C: MicroRNA-497 inhibits the proliferation,
migration and invasion of human bladder transitional cell carcinoma
cells by targeting E2F3. Oncol Rep. 36:1293–1300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shin SS, Park SS, Hwang B, Kim WT, Choi
YH, Kim WJ and Moon SK: MicroRNA-106a suppresses proliferation,
migration, and invasion of bladder cancer cells by modulating MAPK
signaling, cell cycle regulators, and Ets-1-mediated MMP-2
expression. Oncol Rep. 36:2421–2429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H,
Cao Q, Tao L, Meng X, Ju X, et al: miR-154 inhibits prostate cancer
cell proliferation by targeting CCND2. Urol Oncol. 32:31.e9–31.e16.
2014. View Article : Google Scholar
|
|
14
|
Xin C, Zhang H and Liu Z: miR-154
suppresses colorectal cancer cell growth and motility by targeting
TLR2. Mol Cell Biochem. 387:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin X, Yang Z, Zhang P, Liu Y and Shao G:
miR-154 inhibits migration and invasion of human non-small cell
lung cancer by targeting ZEB2. Oncol Lett. 12:301–306.
2016.PubMed/NCBI
|
|
16
|
Wang L, Wu L and Wu J: Downregulation of
miR-154 in human glioma and its clinicopathological and prognostic
significance. J Int Med Res. 44:994–1001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kai Y, Qiang C, Xinxin P, Miaomiao Z and
Kuailu L: Decreased miR-154 expression and its clinical
significance in human colorectal cancer. World J Surg Oncol.
13:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.PubMed/NCBI
|
|
19
|
Xiong F, Liu K, Zhang F, Sha K, Wang X,
Guo X and Huang N: MiR-204 inhibits the proliferation and invasion
of renal cell carcinoma by inhibiting RAB22A expression. Oncol Rep.
35:3000–3008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Dai W and Song J: miR-1182
inhibits growth and mediates the chemosensitivity of bladder cancer
by targeting hTERT. Biochem Biophys Res Commun. 470:445–452. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu H, Fei D, Zong S and Fan Z:
MicroRNA-154 inhibits growth and invasion of breast cancer cells
through targeting E2F5. Am J Transl Res. 8:2620–2630.
2016.PubMed/NCBI
|
|
22
|
Pang X, Huang K, Zhang Q, Zhang Y and Niu
J: miR-154 targeting ZEB2 in hepatocellular carcinoma functions as
a potential tumor suppressor. Oncol Rep. 34:3272–3279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai
H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by
targeting HMGA2 in prostate cancer cells. Mol Cell Biochem.
379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shih IeM, Sheu JJ, Santillan A, Nakayama
K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG,
et al: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP,
in ovarian carcinoma. Proc Natl Acad Sci USA. 102:pp. 14004–14009.
2005; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cosma MP, Tanaka T and Nasmyth K: Ordered
recruitment of transcription and chromatin remodeling factors to a
cell cycle- and developmentally regulated promoter. Cell.
97:299–311. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shamay M, Barak O, Doitsh G, Ben-Dor I and
Shaul Y: Hepatitis B virus pX interacts with HBXAP, a PHD finger
protein to coactivate transcription. J Biol Chem. 277:9982–9988.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maeda D, Chen X, Guan B, Nakagawa S, Yano
T, Taketani Y, Fukayama M, Wang TL and Shih IeM: Rsf-1 (HBXAP)
expression is associated with advanced stage and lymph node
metastasis in ovarian clear cell carcinoma. Int J Gynecol Pathol.
30:30–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH,
Lai MT, Wang TL and Shih IeM: Rsf-1, a chromatin remodelling
protein, interacts with cyclin E1 and promotes tumour development.
J Pathol. 229:559–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren J, Chen QC, Jin F, Wu HZ, He M, Zhao
L, Yu ZJ, Yao WF, Mi XY, Wang EH, et al: Overexpression of Rsf-1
correlates with pathological type, p53 status and survival in
primary breast cancer. Int J Clin Exp Pathol. 7:5595–5608.
2014.PubMed/NCBI
|
|
30
|
Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH,
Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, et al: Rsf-1/HBXAP
overexpression is independent of gene amplification and is
associated with poor outcome in patients with urinary bladder
urothelial carcinoma. J Clin Pathol. 65:802–807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Li G, Liu C, Tang Y and Zhang S:
RSF1 regulates the proliferation and paclitaxel resistance via
modulating NF-κB signaling pathway in nasopharyngeal carcinoma. J
Cancer. 8:354–362. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ito Y: RUNX genes in development and
cancer: Regulation of viral gene expression and the discovery of
RUNX family genes. Adv Cancer Res. 99:33–76. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akech J, Wixted JJ, Bedard K, van der Deen
M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR,
Altieri DC, et al: Runx2 association with progression of prostate
cancer in patients: Mechanisms mediating bone osteolysis and
osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pratap J, Wixted JJ, Gaur T, Zaidi SK,
Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS,
et al: Runx2 transcriptional activation of Indian Hedgehog and a
downstream bone metastatic pathway in breast cancer cells. Cancer
Res. 68:7795–7802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abdelzaher E and Kotb AF: High
Coexpression of Runt-related transcription factor 2 (RUNX2) and p53
independently predicts early tumor recurrence in bladder urothelial
carcinoma patients. Appl Immunohistochem Mol Morphol. 24:345–354.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lim M, Zhong C, Yang S, Bell AM, Cohen MB
and Roy-Burman P: Runx2 regulates survivin expression in prostate
cancer cells. Lab Invest. 90:222–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ozaki T, Wu D, Sugimoto H, Nagase H and
Nakagawara A: Runt-related transcription factor 2 (RUNX2) inhibits
p53-dependent apoptosis through the collaboration with HDAC6 in
response to DNA damage. Cell Death Dis. 4:e6102013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang Z, Qiu H, Luo L, Liu N, Zhong J, Kang
K and Gou D: miR-34b modulates skeletal muscle cell proliferation
and differentiation. J Cell Biochem. Apr 19–2017.(Epub ahead of
print). doi: 10.1002/jcb.26079. View Article : Google Scholar
|
